Wake Forest School of Medicine, Bowman Gray Center for Medical Education, Winston-Salem, North Carolina.
Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida.
Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C279-C281. doi: 10.1152/ajpcell.00478.2020. Epub 2021 Jan 27.
Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry, making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV-2, making native ACE2 on cell surfaces available to convert angiotensin II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
可溶性血管紧张素转换酶 2（sACE2）可能是治疗 2019 年冠状病毒病（COVID-19）感染的一种治疗选择。严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）利用细胞表面上的 ACE2 受体获得细胞内进入，使其成为治疗的理想目标。使用高通量诱变工程设计的高亲和力 sACE2 变体能够作为诱饵受体中和 COVID-19 感染。这些变体通过与 SARS-CoV-2 的刺突（S）蛋白结合与细胞表面上的天然 ACE2 竞争，使细胞表面上的天然 ACE2 能够将血管紧张素 II 转化为血管紧张素-1,7，从而减轻与 COVID-19 感染相关的过度炎症反应。本文探讨了使用 sACE2 作为 COVID-19 感染潜在治疗方法的可能性。
